SCHEMBL24285757

SCHEMBL24285757

C=CC(=O)N1CCCC(n2ccc3ccc(-c4cc(O)cc5ccccc45)cc32)C1

nearest known ligand 0.44

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
BTK Q06187 14/20 0.44
EGFR P00533 4/20 0.43
ITK Q08881 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29445308 1.00 BTK (0.44) BTKEGFRITK
SCHEMBL29445296 0.93 BTK (0.44) BTKEGFRITK
SCHEMBL20445057 0.93 BTK (0.44) BTKEGFRITK
SCHEMBL20444913 0.88 EGFR (0.43) BTKEGFR
SCHEMBL29445286 0.88 EGFR (0.43) BTKEGFR
SCHEMBL29445264 0.83 KDM4E (0.39) BTKEGFR
SCHEMBL20444950 0.83 KDM4E (0.39) BTKEGFR
SCHEMBL20445060 0.82 KRAS (0.39) BTKEGFRITK
SCHEMBL29445253 0.82 KRAS (0.39) BTKEGFRITK
SCHEMBL24285820 0.81 EGFR (0.46) BTKEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11279689-B2 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer ARAXES PHARMA LLC (US) 2022-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11279689-B2 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer KRAS, NRAS, HRAS BTK 1384/4885EGFR 113/4885ITK 3662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.